Holdings

Aisling Capital Management LP

As of Sep 30, 2026, Aisling Capital Management LP reported 13 positions worth US$295M. Largest: BridgeBio Pharma, Inc., Syndax Pharmaceuticals, Inc. and COMPASS Pathways Plc. What it bought and sold, with each filing.

CompanySharesValue as reportedChangeAs of
BridgeBio Pharma, Inc.3.09MUS$203M−1.5MSep 30, 2026
Syndax Pharmaceuticals, Inc.1.32MUS$24.8Mno changeSep 30, 2026
COMPASS Pathways Plc1.73MUS$21.6MnewSep 30, 2026
Monte Rosa Therapeutics, Inc.1.56MUS$18.6Mno changeSep 30, 2026
Bicara Therapeutics Inc.549KUS$10.2M−20,000Sep 30, 2026
BridgeBio Oncology Therapeutics, Inc.1.02MUS$4.14Mno changeSep 30, 2026
Eupraxia Pharmaceuticals, Inc.325KUS$2.96Mno changeSep 30, 2026
Biomea Fusion, Inc.2.05MUS$2.74Mno changeSep 30, 2026
Aclaris Therapeutics, Inc.434KUS$2.29Mno changeSep 30, 2026
Scholar Rock Holding Corporation42,031US$2.03M−35,000Sep 30, 2026